The GLUMON Project

Project at a Glance

Project Acronym: GLUMON
Project Title: Next generation in-blood glucose monitoring using non-invasive optoacoustic sensing
Grant Number: 101058111
Program: Horizon - European Innovation Council - 2021 - Transition Challenges
EU Contribution: € 2 194 210,00
Start Date: May 1, 2022
Project Duration: 48 Months

Endocrine disorders present an increased prevalence in the global population. Diabetes alone affect more than half a million people worldwide – 1 in 10 adults are now living with diabetes. One of the best proxies for diabetes detection, prevention, and monitoring is glucose levels on the bloodstream. Currently, technology only allows us to accurately determine glucose concentration in the bloodstream directly from blood samples (finger-prick). Non-invasive glucose monitoring devices on the market are based on transdermal sensing, measuring glucose in the interstitial fluid. However, glucose concentration in interstitial fluid is diluted in comparison to blood, and the dilution factor depends on individual and temporal characteristics, such as hydration-level. Other limitations include the signal fluctuations with pH, skin irritation, and the need to replace the sensor after a period of use. Therefore, monitoring glucose in bodily fluids other than blood limits the accuracy and reproducibility of such methods, and requires frequent calibration with invasive finger-prick measurements.

GLUMON aims to leverage a new class of a biomedical optoacoustic sensor, developed under the FET project RSENSE (GA #862811), to offer the next generation in-blood non-invasive biochemical sensing in-vivo, thus addressing the limitations of existing biomedical sensors. A driving innovation is the ability to reject signal/data contamination from the skin surface and non-invasively detect glucose directly in vasculature-rich skin layers, effectively offering in-blood glucose monitoring abilities.

The objectives of the GLUMON project are to:

  1. mature the technology from a lab bench-top setup to a functional portable sensor prototype;
  2. improve its market readiness level;
  3. validate and demonstrate the sensor in the lab as well as in preclinical and clinical settings;
  4. develop a sound business case and exploitation strategy; and
  5. address regulatory and ethical requirements for this medical device in preparation for the next phase.